What happened with XNCR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Xencor discovers and develops antibody treatments for cancer and autoimmune diseases. Its XmAb technology replaces parts of an antibody to change how it works, including helping it remain in the body longer or bind to more than one target. Xencor takes selected candidates into clinical trials and licenses others to pharmaceutical companies; it also licenses the technology for partners to use in their own drug development.
Partners pay for these rights through upfront fees, payments when development or commercial milestones are reached, and royalties tied to drug sales. Royalties account for most revenue, with Alexion’s Ultomiris supplying the largest share. Incyte’s Monjuvi also generates royalties, and its development and approvals generate milestone payments.
Xencor has not generated sales revenue from its own products, and most programs remain in early development. Further earnings depend on partners continuing their programs, candidates passing trials and gaining regulatory approval, and marketed drugs selling. Xencor also relies on outside providers for much of its development work and manufacturing. Exclusive licensing agreements can limit its ability to partner the same or similar programs with other companies.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Xencor depends on clinical success turning into partner milestones and royalties; Roche/Genentech, absent from this list, is another important partner and rival in bispecific antibodies.
Zenas BioPharma develops obexelimab licensed from Xencor, so its progress matters both to Xencor’s potential milestone and royalty income and to its Zenas shareholding. Obexelimab could bring Xencor up to $460 million in future milestones, plus royalties if commercialized.
Incyte develops and sells Xencor-licensed tafasitamab as Monjuvi, making its sales and regulatory progress direct sources of Xencor revenue. In 2025, FDA application acceptance and approval triggered $37.5 million in milestone payments, alongside $10.2 million in estimated non-cash royalties.
AstraZeneca’s Alexion subsidiary sells Ultomiris using Xencor’s Xtend technology, supplying Xencor’s largest disclosed royalty stream. Ultomiris sales are the line to watch for this part of Xencor’s revenue.
Amgen pays Xencor for progress on licensed xaluritamig while also developing rival bispecific-antibody platforms. Starting xaluritamig’s Phase 3 study in December 2024 triggered a $30 million milestone that Amgen paid in January 2025.
Johnson & Johnson develops collaboration medicines that could pay Xencor milestones and sales royalties, but also competes in bispecific antibodies for solid tumors. Progress on JNJ-9401 and JNJ-1493 is relevant to Xencor’s partner-developed pipeline; the two agreements carry potential future milestones of $640 million and $636.3 million, respectively.
Vir Biotechnology uses Xencor’s Xtend technology in tobevibart and owes milestones and potential sales royalties, while its solid-tumor T-cell-engaging therapies compete with Xencor’s. Tobevibart’s March 2025 Phase 3 start triggered a $2 million payment to Xencor, paid that second quarter.
Genmab’s DuoBody competes with Xencor’s XmAb in engineered antibodies that bind two targets, and both earn milestones and royalties from partners developing and selling their medicines. Genmab’s partner royalties offer a comparison for Xencor’s licensing model, not payments to Xencor.
Janux Therapeutics competes with Xencor in therapies that enlist T cells against solid tumors and in immune-directed treatments for autoimmune disease. Its early-stage JANX007 and JANX008 cancer trials and JANX011 autoimmune program are the relevant developments, rather than product sales: none of its candidates is approved.
Cullinan Therapeutics competes with Xencor in antibodies that bring T cells to B cells to treat autoimmune disease. Watch CLN-978’s clinical progress; Cullinan describes broader B-cell depletion and off-the-shelf use as potential advantages, not established benefits.
Spyre Therapeutics’ long-acting TL1A antibodies compete with Xencor’s half-life-extended XmAb942 for inflammatory bowel disease. Watch whether Spyre’s clinical results support its proposed quarterly or twice-yearly maintenance injections; those dosing intervals remain potential benefits of its engineering.
Zymeworks competes with Xencor by licensing antibody-engineering technology to partners while developing its own antibodies that bind multiple targets. Its milestone and royalty income from licensed assets such as Ziihera and pasritamig provides a comparison for how partner-funded development can support Xencor’s own pipeline.
CytomX Therapeutics competes with Xencor in engineered cancer therapies that enlist T cells, and both license antibody technology to drug-company partners. CytomX’s PROBODY approach masks a medicine’s binding site until it reaches the tumor environment, making its clinical progress a comparison for efforts to limit activity in healthy tissue.
MacroGenics competes with Xencor in developing and licensing engineered antibodies, including cancer treatments that enlist T cells. Its DART platform makes antibodies that bind two targets, while collaborator funding and paid antibody-manufacturing services help support its operations.
Context Therapeutics competes with Xencor in antibodies that connect T cells to solid tumors, including CLDN6-directed programs. Its Phase 1 CTIM-76 trial is the closest comparison for Xencor’s XmAb541; Context’s proposed ability to target tumors across low, medium and high CLDN6 expression remains a company-stated possibility.
Incyte Genomics Inc earningsINCY
Incyte sells Monjuvi, which uses an antibody licensed from Xencor, so its report can show how the medicine’s sales are shaping Xencor’s royalty income.
Watch Incyte’s reported Monjuvi sales. Rising sales would support more royalty income for Xencor; weakening sales would mean less support from this partnership. The drug’s sales and the royalties Xencor recognizes need not move in step in the same quarter.
AstraZeneca PLC earningsAZN
AstraZeneca’s Alexion sells Ultomiris using Xencor’s Xtend technology, so its report can show how the drug’s sales support Xencor’s largest disclosed royalty stream.
Watch AstraZeneca’s reported Ultomiris sales and relate them to Xencor’s partner-derived royalty income. Stronger sales would support this important royalty source; weaker sales would mean less support for that source of Xencor’s revenue.
Amgen Inc earningsAMGN
Amgen is developing Xencor-licensed xaluritamig, and its report can show whether the program is advancing toward development milestones that could lead to payments to Xencor.
Watch for Amgen’s update on xaluritamig’s development. Progress would show the partner is advancing the program and could bring Xencor closer to future milestone payments; a pause or no new progress would leave those payments uncertain, not earned revenue.
Spyre Therapeutics, Inc. earningsSYRE
Spyre Therapeutics is developing long-acting TL1A antibodies that compete with Xencor’s XmAb942, and its report can show whether clinical progress supports the proposed longer dosing intervals.
Watch Spyre’s clinical updates and what they show about maintenance dosing. Support for quarterly or twice-yearly injections would give Spyre a potential convenience point of competition with Xencor’s XmAb942; without supporting evidence, that proposed advantage remains unproven.
Xencor, Inc. earningsThis company
Xencor earns royalties and milestone payments from partners, and this report shows how much those payments support its research and development spending.
Read partner revenue alongside research and development spending, and remember that recognizing revenue does not always mean receiving cash at the same time. Rising royalties or milestone revenue relative to spending would show that partner programs are supporting more of Xencor’s research; falling or lagging revenue would leave the company relying more on its existing funds and uncertain future payments.
Context Therapeutics Inc. earningsCNTX
Context Therapeutics’ CTIM-76 and Xencor’s XmAb541 both target CLDN6-related solid tumors, so its report can show whether clinical evidence supports treating tumors with different CLDN6 expression levels.
Watch Context’s update on the Phase 1 CTIM-76 trial and whether the data cover tumors with low, medium and high CLDN6 expression. Evidence across those levels would better support Context’s proposed reach and give Xencor’s XmAb541 a direct comparison; narrower or insufficient evidence would leave that potential advantage unproven.
Vir Biotechnology, Inc. earningsVIR
Vir Biotechnology uses Xencor’s Xtend technology in tobevibart, and its report can show whether the program’s progress brings new milestone opportunities and affects potential future royalties for Xencor.
Watch Vir’s update on tobevibart’s clinical progress. Further advancement could bring Xencor closer to later milestone payments; sales could also generate royalties if the medicine reaches the market. A stall would leave those potential revenues distant and uncertain.
Cullinan Therapeutics, Inc. earningsCGEM
Cullinan Therapeutics’ CLN-978 competes with Xencor’s programs for autoimmune disease, and its report can show how far this competing treatment approach has advanced clinically.
Watch Cullinan’s update on CLN-978 and whether evidence supports its claimed potential for broader B-cell depletion. Progress would show another competing approach advancing in Xencor’s autoimmune-disease field; limited progress would provide less evidence of that competitive pressure.
Zenas BioPharma, Inc. earningsZBIO
Zenas BioPharma is developing obexelimab under a license from Xencor, and its report can show whether progress brings Xencor closer to potential milestone payments and future royalties.
Watch Zenas’s update on obexelimab’s clinical development. Progress could bring Xencor closer to future milestone payments; if the medicine eventually reaches the market, sales could also generate royalties. Delays would leave those potential revenues more uncertain, not earned income.
